Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results Consulting agrmnt CC transcript Asset disposition Director departure Appointed COO Appointed director
|
DENDREON CORP (DNDNQ)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
06/10/2015 |
8-K
| Form 8-K - Current report |
06/03/2015 |
8-K
| Bankruptcy or Receivership, Material Modifications to Rights of Security Holders, Regulation FD Disclosure, Financial Stateme... |
06/02/2015 |
8-K
| Regulation FD Disclosure |
05/21/2015 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits |
04/21/2015 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
04/17/2015 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
04/08/2015 |
8-K
| Other Events |
03/25/2015 |
8-K
| Asset disposition |
03/11/2015 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
03/06/2015 |
8-K
| Other Events, Financial Statements and Exhibits |
02/27/2015 |
8-K
| Resignation/termination of a director |
02/25/2015 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
02/25/2015 |
4
| Brophy Karen (VP, Human Resources) has filed a Form 4 on DENDREON CORP
Txns:
| Paid exercise price by delivering 758 shares
@ $0.05, valued at
$37.9 Paid exercise price by delivering 20,217 shares
@ $0.05, valued at
$1k
Paid exercise price by delivering 1,137 shares
@ $0.05, valued at
$56.9 |
|
02/23/2015 |
8-K
| Resignation/termination of a director |
02/20/2015 |
8-K
| Regulation FD Disclosure |
02/20/2015 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
02/19/2015 |
4
| Brophy Karen (VP, Human Resources) has filed a Form 4 on DENDREON CORP
Txns:
| Sold 2,309 shares
@ $0.0723, valued at
$166.9 Sold 3,823 shares
@ $0.0705, valued at
$269.5 |
|
02/19/2015 |
8-K
| Regulation FD Disclosure |
02/18/2015 |
4
| Crotty Robert (EVP, General Counsel) has filed a Form 4 on DENDREON CORP
Txns:
| Sold 21,764 shares
@ $0.0811, valued at
$1.8k
|
|
02/18/2015 |
4
| Pacheco Silvio (SVP, Sales and Marketing) has filed a Form 4 on DENDREON CORP
Txns:
| Sold 2,500 shares
@ $0.081, valued at
$202.5 Sold 3,222 shares
@ $0.069, valued at
$222.3 |
|
02/17/2015 |
4
| Monteith William (EVP, Technical Operations) has filed a Form 4 on DENDREON CORP |
02/17/2015 |
4
| Cox Greg (EVP, CFO & Treasurer) has filed a Form 4 on DENDREON CORP |
02/17/2015 |
4
| Sandler Andrew Seth (EVP, Chief Medical Officer) has filed a Form 4 on DENDREON CORP
Txns:
| Sold 7,791 shares
@ $0.0904, valued at
$704.3 Sold 105,925 shares
@ $0.0894, valued at
$9.5k
|
|
02/17/2015 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits |
02/10/2015 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits |
02/10/2015 |
SC 13G/A
| VANGUARD GROUP INC reports a 0% stake in Dendreon Corp |
02/06/2015 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs:
|
"Amended and Restated Acquisition Agreement, by and among Dendreon Corporation, Dendreon Holdings, LLC, Dendreon Distribution, LLC and Dendreon Manufacturing, LLC, and Valeant Pharmaceuticals International, Inc. (Schedules and exhibits have been omitted from this exhibit pursuant to Item 601(b)(2) of Regulation S-K and are not filed herewith. The registrant hereby agrees to furnish a copy of any omitted schedule or exhibits to the U.S. Securities and Exchange Commission upon request.)",
"Order Approving Stalking Horse Bidder, Authorizing Bid Protections in Connection with the Sale of Substantially All of the Debtors' Assets, Rescheduling the Hearing to Approve Such Sale and Granting Related Relief, entered by the United States Bankruptcy Court for the District of Delaware on February 5, 2015",
"DENDREON ENTERS INTO AMENDED AGREEMENT WITH VALEANT IN CONNECTION WITH COURT-SUPERVISED SALES PROCESS" |
|
02/02/2015 |
4
| Crotty Robert (EVP, General Counsel) has filed a Form 4 on DENDREON CORP
Txns:
| Paid exercise price by delivering 470 shares
@ $0.16, valued at
$75.2 |
|
02/02/2015 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs:
|
"Acquisition Agreement, by and among Dendreon Corporation, Dendreon Holdings, LLC, Dendreon Distribution, LLC and Dendreon Manufacturing, LLC, and Valeant Pharmaceuticals International, Inc. (Schedules and exhibits have been omitted from this exhibit pursuant to Item 601(b)(2) of Regulation S-K and are not filed herewith. The registrant hereby agrees to furnish a copy of any omitted schedule or exhibits to the U.S. Securities and Exchange Commission upon request.)",
"Motion for Order Approving Stalking Horse Bidder, Authorizing Bid Protections in Connection with the Sale of Substantially All of the Debtors' Assets, Rescheduling the Hearing to Approve Such Sale and Granting Related Relief, filed with the United States Bankruptcy Court for the District of Delaware on January 29, 2015",
"DENDREON REACHES AGREEMENT FOR VALEANT TO SERVE AS “STALKING HORSE BIDDER” IN COURT-SUPERVISED SALES PROCESS" |
|
01/27/2015 |
8-K
| Regulation FD Disclosure |
01/22/2015 |
8-K
| Other Events |
01/21/2015 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
01/21/2015 |
4
| Monteith William (EVP, Technical Operations) has filed a Form 4 on DENDREON CORP |
01/21/2015 |
4
| Cox Greg (VP, Interim CFO & Treasurer) has filed a Form 4 on DENDREON CORP |
|
|
|